About Us
Orion Biotech is dedicated to advancing biomedical solutions through innovative research and development. Our mission is to improve human health and well-being with cutting-edge technology and scientific expertise.
Drug Development Pipelines
Recombinant Type III Human Collagen
Orion Biotech's recombinant Type III human collagen pipeline represents a significant advancement in the production of human collagen. By using human collagen as a gene template our collagen is identical to that is natural produced in human, which gives it outstanding biocompatibility and lasting effects for aesthetic purposes, dermal filling, mesotherapy and dental filling etc.
Seborrheic Dermatitis Treatment
Orion Biotech is pioneering a novel approach to treating seborrheic dermatitis, a condition that has been notoriously difficult to manage. Our innovative method involves competitively inhibiting cytokines to halt the inflammation pathway, providing a new avenue for effective treatment. Our novel molecule SSD624 has shown remarkable efficacy in clinical trials, indicating almost complete remission by the third month, with noticeable improvement observed as early as day one. SSD624 is ready for market release.
Long lasting Hyperuricemia Treatment
Our pipeline for treating hyperuricemia focuses on a novel, long-lasting enzyme that significantly reduces uric acid levels. This enzyme degrades uric acid into allantoin, which is easily excreted from the body. The modified urate oxidase enzyme has a half-life of over a month, compared to the natural enzyme's 18-hour half-life. One injection can maintain reduced uric acid levels for over a month, providing a convenient and effective treatment option. Evenmore, this treatment does not causes liver and kidney damages unlike currently available uric acid reducingg drugs, which provides extra health benefits when rapidly reducingg uric acid levels, especially for those who already have kidney and liver injuries. This pipeline is in the early stages of development.
Feline Infectious Peritonitis (FIP) Treatment Pipeline
Leveraging our expertise in coronavirus research and the insights gained from SARS-CoV-2, Orion Biotech is developing a dual approach to combat Feline Infectious Peritonitis (FIP), an currently untreatable disease in cats. We are developing monoclonal antibodies specifically targeting the FIP virus to provide an effective treatment. In addition to therapeutic antibodies, we are also working on a pre-exposure prophylaxis (PrEP) vaccine to prevent FIP. Both the treatment and prevention pipelines for FIP are in the early development stages.
On-Market Products
Our product catalog includes a range of innovative biomedical solutions designed to improve health and quality of life. Each product is developed with the highest standards of scientific research and clinical validation.
Our People
Academic Consultant: Dr. WANG , Professor of Life Science, Tsinghua University, Specialty in Immunology, Coronavirus, Structural Biology.
Scientific Director: Dr. ZHANG, PhD.Tsinghua University, Specialty in Vaccine and Rabies virus
Business Development Director: WU Zilong, MSc Molecular Biology, Auckland University, Specialty in Stem Cells, Dermatology and hair regeneration
Research & Development
Orion Biotech is People's Biomedical Company, we are not profit oriented, instead we try to solve major illnesses that do not have satisfying treatment at very affordable prices. We also care about lives besides human, Let's hope the best for all living beings.
Contact Us
Interested in distributing, or partnering with us, email us at z.wu@orion-biotech.com.